NYX‐2925, A Novel N‐methyl‐D‐aspartate Receptor Modulator: A First‐in‐Human, Randomized, Double‐blind Study of Safety and Pharmacokinetics in Adults

NYX‐2925, a new chemical entity, acts as a co‐agonist to glutamate at the N‐methyl‐D‐aspartate receptor (NMDAR). At low concentrations of endogenous agonists (glycine/D‐serine), NYX‐2925 partially activates NMDARs, modulating neural pathways relevant for chronic pain. NYX‐2925 is being developed for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Sci
Main Authors: Houck, David R., Sindelar, Laurel, Sanabria, Carlos R., Stanworth, Stephanie H., Krueger, Maggie, Suh, Mary, Madsen, Torsten M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440576/
https://ncbi.nlm.nih.gov/pubmed/30242962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12584
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados